Dr. Pennell on Guidelines, Barriers, and Access to Molecular Testing in NSCLC
June 7, 2019
Cancer Network spoke with Nathan A. Pennell, MD, PhD, of Cleveland Clinic at ASCO 2019 regarding current use of and barriers to molecular testing in NSCLC.
Nathan A. Pennell, MD, PhD
Time to Move Beyond Clinical and Pathologic Classification of BAC
September 22, 2010
Bronchioloalveolar carcinoma (BAC) is a unique subtype of lung adenocarcinoma that has received increasing attention in recent years. Levy and colleagues have provided a comprehensive review of the clinical and pathologic characteristics of this disease, as well as the clinical evidence available to guide treatment of patients with BAC.
